Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is pleased to announce that it has received the ...
TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Arun Menawat, CEO of Profound Medical, talks about the company’s innovative TULSA-PRO technology. In a recent interview, Arun Menawat, CEO of Profound Medical, discussed the company’s innovative TULSA ...
Results from the PROfound phase III study, funded by AstraZeneca and Merck Sharp & Dohme, open up a much-needed new treatment avenue for the more precise and effective treatment of patients with ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...
ORLANDO, Fla. — Up to half of all people with severe chronic hand eczema (CHE) who apply delgocitinib cream (Anzupgo) to their hands twice a day have had a profound response to treatment, and about a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results